JBIO
The table below shows Jade Biosciences, Inc.'s balance sheet line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & equivalents | $88.44M | $33.75M | $23.49M | $22.40M | $54.20M |
| Short-term investments | $247.72M | $44.87M | $98.95M | $106.82M | $113.18M |
| Receivables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Total current assets | $348.82M | $80.12M | $124.23M | $131.50M | $174.33M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Property, plant & equipment | $170.00K | $6.00K | $288.00K | $242.00K | $186.00K |
| Goodwill | - | - | - | - | - |
| Total assets | $349.78M | $80.33M | $127.42M | $135.30M | $175.36M |
| Accounts payable | $2.15M | $224.00K | $2.40M | $2.58M | $1.21M |
| Total current liabilities | $16.54M | $3.83M | $17.64M | $7.78M | $2.55M |
| Long-term debt | - | - | - | - | - |
| Total liabilities | $17.26M | $3.90M | $17.96M | $8.56M | $2.94M |
| Retained earnings | -$174.39M | -$233.05M | -$163.42M | -$87.90M | -$36.39M |
| Total equity | $332.52M | $76.43M | $109.46M | $126.74M | $172.42M |